



Molecular Insights into Depression

Guest Editors:

Dr. Yu-Cheng Ho

School of Medicine, College of
Medicine, I-Shou University,
Kaohsiung City 82445, Taiwan

Dr. Cheng-Chun Wu

School of Medicine, College of
Medicine, I-Shou University,
Kaohsiung City, Taiwan

Dr. Ming Tatt Lee

Faculty of Pharmaceutical
Sciences, UCSI University, Kuala
Lumpur, Malaysia

Deadline for manuscript
submissions:

30 June 2024

Message from the Guest Editors

Psychiatric disorders, including major depressive disorder (MDD), are the leading cause of disability worldwide, affecting an estimated 120 million people around the world. Environmental risk factors such as stress play an important role in the etiology of MDD. Moreover, the high degree of susceptibility suggests a significant contribution to the dysregulation of brain function. The major challenges in managing people with depression are due to the complexity and heterogeneity of this disorder, the poor response of some sufferers to available treatments, and a lack of objective biomarkers.

This Special Issue will collate studies of depression-related research focusing on several aspects, including, but not limited to, depression, stress, neural circuits, animal models, therapeutic strategies, biomarkers of depression, behavioral despair, anhedonia, and antidepressants, as well as psychiatric disorders. Both original research and review articles are welcome. We warmly encourage you to propose novel functional studies elucidating the molecular mechanisms and pharmacotherapeutic strategies that could help to untangle the complex etiology of psychiatric disorders.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)